Summit trials gain credibility after Akeso Phase 3 data, Guggenheim says
Guggenheim said Summit’s global lung cancer trials gained credibility following Akeso’s Phase 3 data, per TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.